Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fotemustine versus fotemustine + ipilimumab in metastatic melanoma with brain metastases
2012-004301-27Phase 3Terminated
- Sponsor
- Fondazione NIBIT
- Start
- Oct 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in melanoma and brain metastases comparing Fotemustine with Fotemustine + ipilimumab (2 arms). Primary endpoint: Overall survival. Started Oct 2012; status: terminated.
02
Drugs
fotemustineipilimumab
03
Conditions
melanomabrain metastases
Beyond the preview
Go deeper on 2012-004301-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004301-27.